Alert: Eli Lilly's Multi-Billion Acquisition of 5-MeO-DMT Developer Signals Major Pharma Push

Eli Lilly has acquired AtaiBeckley, developer of intranasal 5-MeO-DMT (BPL-003), for up to $3.8 billion, marking the largest psychedelic buyout to date and signaling a significant mainstream pharmaceutical investment in psychedelic-assisted therapies. Milestone payments are tied to FDA approval and DEA rescheduling of both BPL-003 and a DMT-based candidate (VLS-01), indicating a clear path toward medical integration for these controlled substances. This development suggests a strong push for formal regulatory pathways, potentially setting precedents for future legislative and compliance requirements across the psychedelic industry.